Morgan Stanley analyst Cecilia Furlong downgrades Baxter Intl (NYSE:BAX) from Overweight to Equal-Weight and announces $55 price target.
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data In An Oral Presentation At The International Conference On Malignant Lymphoma Lugano
Presentation Includes Data on All 33 CAR T-Naïve Patients Treated with the Alloy™ Manufactured Material and Recaps Data on 12 Large B Cell Lymphoma Patients Treated with Phase 2 Dose RegimenResults Indicate an
